Bayer's Science Is Moving Faster Than Its Earnings—and Wall Street Knows the Difference

Bayer has plenty to talk about this month. A pipeline readout, a regulatory filing, a court skirmish, and a pair of bullish analyst notes all landed within days of each other. None of them, however, answers the question that will actually move the stock: whether the company's profit trajectory is stabilizing.

That test arrives on November 3, when Bayer reports third-quarter 2026 results.

Finerenone data add clinical weight, not revenue certainty

The most recent scientific update came from subgroup analyses of the Phase III FIND-CKD trial, which Bayer disclosed yesterday. According to the company, the data reinforce finerenone's kidney-protective effect in chronic kidney disease without diabetes. In the FSGS subgroup, Bayer reported both a reduction in proteinuria and a slower decline in kidney function—two distinct aspects of disease progression rather than a single measurement.

The key detail is the patient population: these results address non-diabetic CKD specifically, sharpening the picture of where finerenone could eventually be used. They stem from subgroup analyses and should be read as such. For investors, the takeaway is medical, not commercial—no revenue contribution can be inferred from these findings alone.

Should investors sell immediately? Or is it worth buying Bayer?

Regulatory momentum is building in parallel. Roughly two weeks ago, the U.S. Food and Drug Administration accepted Bayer's supplemental application for finerenone in chronic kidney disease without diabetes, a filing built on the FIND-CKD study. Acceptance is a procedural step, not an approval, and it does not substitute for proof that the operating business is holding up.

Two bullish calls, one unresolved problem

JPMorgan kept Bayer at "Overweight" on October 16 with a price target of 61 euros. Analyst Richard Vosser sees revenue running 2% above consensus but EBITDA 6% below it—a split verdict that pairs a constructive long-term view with caution on near-term profitability. A day earlier, UBS reiterated "Buy" with a 62-euro target. Neither move was an upgrade; both reflect existing convictions rather than fresh evidence of improvement.

Those convictions face an awkward backdrop. Media reports on October 13 indicated that analyst estimates for Bayer's earnings per share had fallen since the start of August. That makes the EPS line the number to watch on November 3. Beating a lowered bar is not the same as growing against prior periods, and the market will treat the two very differently.

The farm economy is not cooperating

Pressure from agriculture adds a second layer of risk. On October 15, FMC cut its outlook sharply—a warning that, according to media reports, also weighed on Bayer shares. The read-across offers no basis for quantifying any specific hit to Bayer, nor does it explain every subsequent price move.

The broader picture is no friendlier. A study commissioned by Bayer concluded about a week ago that production growth in the EU and the UK is lagging behind major agricultural markets, with geopolitical and climatic strains compounding the challenge. None of this proves an earnings miss at Bayer. It does argue against assuming the farm downturn has bottomed.

Bayer at a turning point? This analysis reveals what investors need to know now.

Latham pushes back in court

On the legal front, Latham Quality has asked a U.S. federal court to reject Bayer's motion to dismiss its antitrust suit over NK603 seed licenses, according to media reports. The filing, dated October 16, follows Bayer's dismissal request lodged in July. This is one side's argument, not a ruling—a distinction worth keeping in mind as the case proceeds.

What November 3 has to settle

Strip away the headlines and the setup is straightforward. Optimists point to a 61-euro target from JPMorgan, a 62-euro target from UBS, encouraging kidney-disease data, and an FDA filing under review. Sceptics point to downgraded profit estimates, a weakening farm economy, and litigation that refuses to go away.

The quarterly report will not resolve the long-term debate. It will, however, show whether the reduced earnings expectations are a floor or a waypoint. If Bayer stabilizes the operating picture and avoids further guidance cuts, the bullish case gains credibility. If profit momentum slips again, price targets alone will offer little comfort.

Ad

Bayer Stock: New Analysis - 23 October

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...